Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-cash Items (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Non-cash Items for 4 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items rose 113.48% to $4.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.6 million, a 113.48% increase, with the full-year FY2025 number at $4.6 million, up 113.48% from a year prior.
  • Non-cash Items was $4.6 million for Q4 2025 at Phathom Pharmaceuticals, down from $18.8 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $51.6 million in Q3 2024 to a low of $170000.0 in Q1 2023.
  • A 4-year average of $13.5 million and a median of $7.7 million in 2024 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: crashed 89.87% in 2023, then skyrocketed 1465.76% in 2024.
  • Phathom Pharmaceuticals' Non-cash Items stood at $4.5 million in 2022, then skyrocketed by 241.82% to $15.3 million in 2023, then crashed by 86.06% to $2.1 million in 2024, then surged by 113.48% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Non-cash Items are $4.6 million (Q4 2025), $18.8 million (Q3 2025), and $25.3 million (Q2 2025).